JP2018524373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524373A5 JP2018524373A5 JP2018501976A JP2018501976A JP2018524373A5 JP 2018524373 A5 JP2018524373 A5 JP 2018524373A5 JP 2018501976 A JP2018501976 A JP 2018501976A JP 2018501976 A JP2018501976 A JP 2018501976A JP 2018524373 A5 JP2018524373 A5 JP 2018524373A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- construct
- binding
- binding polypeptide
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 344
- 102000036639 antigens Human genes 0.000 claims description 344
- 108091007433 antigens Proteins 0.000 claims description 344
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 157
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 150
- 229920001184 polypeptide Polymers 0.000 claims description 148
- 239000000203 mixture Substances 0.000 claims description 79
- 239000003814 drug Substances 0.000 claims description 78
- 229940079593 drug Drugs 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 59
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 58
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 57
- 150000001413 amino acids Chemical class 0.000 claims description 52
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 46
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 32
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 32
- 238000012986 modification Methods 0.000 claims description 20
- 230000004048 modification Effects 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000000099 in vitro assay Methods 0.000 claims description 13
- 229960003008 blinatumomab Drugs 0.000 claims description 12
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims description 11
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 10
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 10
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 10
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 10
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 10
- 102100024153 Cadherin-15 Human genes 0.000 claims description 9
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 claims description 9
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 7
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 7
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 5
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 102100031013 Transgelin Human genes 0.000 claims description 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009490 IgG Receptors Human genes 0.000 claims description 4
- 108010073807 IgG Receptors Proteins 0.000 claims description 4
- 102000029749 Microtubule Human genes 0.000 claims description 4
- 108091022875 Microtubule Proteins 0.000 claims description 4
- 230000002101 lytic effect Effects 0.000 claims description 4
- 210000004688 microtubule Anatomy 0.000 claims description 4
- 229950010127 teplizumab Drugs 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 229940127174 UCHT1 Drugs 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 101000642536 Apis mellifera Venom serine protease 34 Proteins 0.000 claims description 2
- 208000037914 B-cell disorder Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 101000633445 Homo sapiens Structural maintenance of chromosomes protein 2 Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 241000282577 Pan troglodytes Species 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 102100029540 Structural maintenance of chromosomes protein 2 Human genes 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930188854 dolastatin Natural products 0.000 claims description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 229940050282 inebilizumab-cdon Drugs 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 29
- 101100372806 Caenorhabditis elegans vit-3 gene Proteins 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 35
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 239000003053 toxin Substances 0.000 description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000011577 humanized mouse model Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 1
- WEZNQZHACPSMEF-QEJZJMRPSA-N Ala-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-QEJZJMRPSA-N 0.000 description 1
- 108010080422 CD39 antigen Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193056P | 2015-07-15 | 2015-07-15 | |
| US62/193,056 | 2015-07-15 | ||
| US201562193569P | 2015-07-16 | 2015-07-16 | |
| US62/193,569 | 2015-07-16 | ||
| PCT/CA2016/050839 WO2017008169A1 (en) | 2015-07-15 | 2016-07-15 | Drug-conjugated bi-specific antigen-binding constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018524373A JP2018524373A (ja) | 2018-08-30 |
| JP2018524373A5 true JP2018524373A5 (enExample) | 2019-08-22 |
Family
ID=57756601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501976A Pending JP2018524373A (ja) | 2015-07-15 | 2016-07-15 | 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11147886B2 (enExample) |
| EP (1) | EP3322735A4 (enExample) |
| JP (1) | JP2018524373A (enExample) |
| CN (1) | CN108137706A (enExample) |
| CA (1) | CA2991799A1 (enExample) |
| WO (1) | WO2017008169A1 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3283524T3 (da) | 2015-04-17 | 2023-05-30 | Amgen Res Munich Gmbh | BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3 |
| MX383614B (es) | 2015-05-21 | 2025-03-14 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| TWI852735B (zh) | 2015-12-04 | 2024-08-11 | 美商思進公司 | 四級胺化妥布賴森(tubulysin)化合物之結合物 |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| IL268058B2 (en) * | 2017-01-20 | 2023-09-01 | Magenta Therapeutics Inc | Compositions and methods for depleting cd137 plus cells |
| JP2020506700A (ja) | 2017-01-31 | 2020-03-05 | ノバルティス アーゲー | 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療 |
| DK3579848T3 (da) | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| WO2018159582A1 (ja) * | 2017-02-28 | 2018-09-07 | 学校法人近畿大学 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法 |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018217947A1 (en) * | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
| KR20200055770A (ko) * | 2017-09-20 | 2020-05-21 | 메르사나 테라퓨틱스, 인코포레이티드 | Napi2b 표적 요법에 대한 반응을 예측하기 위한 조성물 및 방법 |
| KR20200086278A (ko) | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
| SG11202004512XA (en) | 2017-11-15 | 2020-06-29 | Novartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
| WO2019108900A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
| AU2019215031C1 (en) | 2018-01-31 | 2026-02-26 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| SG11202007579TA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| BR112020023330A2 (pt) | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EP3833385A4 (en) | 2018-08-08 | 2021-12-22 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN |
| PT3844267T (pt) | 2018-08-31 | 2025-09-30 | Novartis Ag | Métodos de preparação de células que expressam recetor de antigénio quimérico |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) * | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| US20220023430A1 (en) * | 2018-11-13 | 2022-01-27 | Lipoxen Technologies Limited | Glycopolysialylation of blinatumomab |
| CN114426578B (zh) * | 2019-02-14 | 2025-03-21 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
| AU2020229806A1 (en) | 2019-02-25 | 2021-07-29 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| CN109776683B (zh) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | 一种双特异性抗体及其制备方法与应用 |
| US20230074800A1 (en) | 2019-03-21 | 2023-03-09 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| JP7688584B2 (ja) * | 2019-04-25 | 2025-06-04 | エフ． ホフマン－ラ ロシュ アーゲー | ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| CN110423723A (zh) * | 2019-07-18 | 2019-11-08 | 南方医科大学南方医院 | 一种外周血b细胞系的构建方法及其应用 |
| EP4031565A4 (en) * | 2019-09-16 | 2023-10-25 | Regents of the University of Minnesota | COMPOUNDS AND METHODS FOR IMMUNOTHERAPY |
| EP4065158A2 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| EP4073122A4 (en) * | 2019-12-11 | 2024-03-27 | Cullinan Oncology, Inc. | Anti-cd19 antibodies and multi-specific binding proteins |
| WO2021121215A1 (en) * | 2019-12-20 | 2021-06-24 | Shandong Boan Biotechnology Co., Ltd. | Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy |
| MX2022010685A (es) | 2020-02-27 | 2022-09-23 | Novartis Ag | Metodos de produccion de celulas que expresan receptores de antigeno quimericos. |
| CN115175695A (zh) | 2020-02-27 | 2022-10-11 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
| AU2021226336A1 (en) * | 2020-02-27 | 2022-08-11 | Phanes Therapeutics, Inc. | Antibodies conjugated with fatty acid molecules and uses thereof |
| AR125758A1 (es) | 2020-04-04 | 2023-08-09 | Janux Therapeutics Inc | Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras |
| CN115836088A (zh) | 2020-05-06 | 2023-03-21 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和clec12a的蛋白质 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
| CN111840571B (zh) * | 2020-08-03 | 2022-09-20 | 杭州皓阳生物技术有限公司 | 一种抗体药物偶联物及其用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| US11197910B1 (en) | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
| TW202227124A (zh) | 2020-08-21 | 2022-07-16 | 瑞士商諾華公司 | 用於體內產生ｃａｒ表現細胞的組成物和方法 |
| KR20230128271A (ko) * | 2020-11-20 | 2023-09-04 | 악티늄 파마슈티컬즈, 인코포레이티드 | 고형 암의 치료를 위한 her3 방사선면역요법 |
| TW202237653A (zh) * | 2020-12-09 | 2022-10-01 | 美商詹努克斯治療有限公司 | 與經腫瘤活化之靶定trop2及效應細胞抗原之抗體相關之組合物及方法 |
| JP2024506022A (ja) * | 2021-02-08 | 2024-02-08 | シンアフィックス ビー．ブイ． | 多機能性抗体 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| WO2022199555A1 (en) * | 2021-03-23 | 2022-09-29 | Guangzhou Lintonpharm Co., Ltd. | A multispecific antigen binding protein binding to cd3 and the use thereof |
| TW202309294A (zh) | 2021-04-27 | 2023-03-01 | 瑞士商諾華公司 | 病毒載體生產系統 |
| WO2022240865A1 (en) * | 2021-05-11 | 2022-11-17 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| KR20240007939A (ko) * | 2021-05-13 | 2024-01-17 | 우시 바이올로직스 아일랜드 리미티드 | 항-p-카드헤린 항체를 포함하는 항체 콘쥬게이트 및 이의 용도 |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| JP2024531364A (ja) | 2021-08-20 | 2024-08-29 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| AU2023218463A1 (en) * | 2022-02-11 | 2024-08-29 | Shenzhen Enduring Biotech , Ltd. | Pegylated antibody hydroxyl-bearing drug conjugate |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| EP4653017A1 (en) | 2023-01-18 | 2025-11-26 | Tyligand Bioscience (Shanghai) Limited | Antibody-drug conjugate and use thereof |
| EP4680648A1 (en) * | 2023-03-17 | 2026-01-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-her3 and anti-met antibodies and uses thereof |
| WO2024193682A1 (en) * | 2023-03-23 | 2024-09-26 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Anti-tpbg/met antibodies and uses thereof |
| WO2025099489A1 (en) * | 2023-11-10 | 2025-05-15 | Ligachem Biosciences Inc. | Antibody-drug conjugate comprising bispecific antibody specifically binding to cd20 and cd22 and uses thereof |
| TW202546005A (zh) * | 2024-01-11 | 2025-12-01 | 美商西雅圖免疫公司 | 抗體-奧瑞他汀藥物偶聯物以及其製造及使用方法 |
| CN120285217A (zh) * | 2024-01-11 | 2025-07-11 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-奥瑞他汀类药物偶联物及其用途 |
| TW202604965A (zh) | 2024-04-24 | 2026-02-01 | 大陸商百奧賽圖(北京)醫藥科技股份有限公司 | 抗ｐｔｋ７／ｂ７ｈ３抗體及其用途 |
| CN119431525B (zh) * | 2024-10-08 | 2025-04-11 | 北京溯本源和生物科技有限公司 | 狂犬病毒g蛋白重组抗原、单克隆抗体及其制备方法和应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| EP1701979A2 (en) * | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
| EA012464B1 (ru) | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Антитело против cd20 и его применение |
| US20090226466A1 (en) | 2005-11-03 | 2009-09-10 | Sherman Fong | Therapeutic anti-her2 antibody fusion polypeptides |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| EP2799449A1 (en) | 2006-05-25 | 2014-11-05 | Bayer Intellectual Property GmbH | Dimeric molecular complexes |
| JP5401314B2 (ja) | 2006-09-08 | 2014-01-29 | メディミューン，エルエルシー | ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用 |
| EP2091975A4 (en) | 2006-11-21 | 2013-05-22 | Univ California | ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE |
| SG10201808730VA (en) * | 2007-04-03 | 2018-11-29 | Amgen Res Munich Gmbh | Cross-species-specific binding domain |
| WO2010001585A1 (en) * | 2008-06-30 | 2010-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| CA2738568C (en) | 2008-10-01 | 2024-02-20 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
| US8455249B2 (en) * | 2009-05-01 | 2013-06-04 | The University Of Tokyo | Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo |
| BR112012009778A2 (pt) | 2009-10-27 | 2017-06-13 | Micromet Ag | regime de dosagem para administrar um anticorpo biespecífico de cd19xcd3 |
| EP2496598B1 (en) | 2009-11-04 | 2017-08-02 | Affibody AB | Her3 binding polypeptides |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| JP2013528357A (ja) | 2010-03-29 | 2013-07-11 | ザイムワークス，インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
| NZ604007A (en) | 2010-05-27 | 2015-03-27 | Genmab As | Monoclonal antibodies against her2 epitope |
| SG187908A1 (en) | 2010-08-20 | 2013-03-28 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| SMT201700250T1 (it) | 2010-11-10 | 2017-07-18 | Amgen Res Munich Gmbh | Prevenzione di effetti avversi provocati da domini leganti cd3 specifici |
| ES2676878T3 (es) | 2011-03-03 | 2018-07-25 | Zymeworks Inc. | Diseño de armazón de heteromultímero multivalente y constructos |
| AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| EP2701741B1 (en) | 2011-04-28 | 2020-06-10 | Amgen Research (Munich) GmbH | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| JP5997151B2 (ja) | 2011-06-30 | 2016-09-28 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| EP3321286B1 (en) | 2011-08-23 | 2021-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| PL2773671T3 (pl) | 2011-11-04 | 2022-01-24 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| JP6351572B2 (ja) | 2012-05-10 | 2018-07-04 | ザイムワークス，インコーポレイテッド | Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物 |
| CN104520327B (zh) | 2012-05-10 | 2019-01-18 | 酵活有限公司 | 单臂单价抗体构建体及其用途 |
| US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| AU2013289881B2 (en) | 2012-07-13 | 2018-01-18 | Zymeworks Bc Inc. | Multivalent heteromultimer scaffold design and constructs |
| US20140154253A1 (en) | 2012-07-13 | 2014-06-05 | Zymeworks Inc. | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs |
| CA2878587A1 (en) | 2012-07-23 | 2014-01-30 | Zymeworks Inc. | Immunoglobulin constructs comprising selective pairing of the light and heavy chains |
| US9382329B2 (en) * | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| MX385344B (es) | 2012-11-28 | 2025-03-18 | Zymeworks Bc Inc | Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos. |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| AU2014262566A1 (en) | 2013-05-08 | 2015-11-12 | Zymeworks Inc. | Bispecific HER2 and HER3 antigen binding constructs |
| CN105531374A (zh) * | 2013-07-12 | 2016-04-27 | 酵活有限公司 | 双特异性cd3和cd19抗原结合构建体 |
| CN104341504B (zh) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
| EP4570318A3 (en) | 2013-11-27 | 2025-10-15 | Zymeworks BC Inc. | Bispecific antigen-binding constructs targeting her2 |
| US20160326249A1 (en) * | 2014-01-15 | 2016-11-10 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| KR20170010863A (ko) * | 2014-07-01 | 2017-02-01 | 화이자 인코포레이티드 | 이중특이성 이종이량체성 디아바디 및 이의 용도 |
-
2016
- 2016-07-15 CA CA2991799A patent/CA2991799A1/en not_active Abandoned
- 2016-07-15 CN CN201680053451.9A patent/CN108137706A/zh active Pending
- 2016-07-15 JP JP2018501976A patent/JP2018524373A/ja active Pending
- 2016-07-15 US US15/741,984 patent/US11147886B2/en not_active Expired - Fee Related
- 2016-07-15 WO PCT/CA2016/050839 patent/WO2017008169A1/en not_active Ceased
- 2016-07-15 EP EP16823604.0A patent/EP3322735A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7592660B2 (ja) | 改善された内部移行特性を有する多重特異性抗原結合分子 | |
| US20230105802A1 (en) | Anti-ntb-a antibodies and related compositions and methods | |
| TWI872065B (zh) | 雙互補位ＦＲ－α抗體及免疫結合物 | |
| TWI593707B (zh) | Ｃｄ３３抗體類及彼等於治療癌症之用途 | |
| KR102514317B1 (ko) | 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법 | |
| DK3102606T3 (en) | ANTIBODY MEDICINAL CONJUGATES AND IMMUNTOXINES | |
| US20230235071A1 (en) | Anti-CD30 Antibodies and Methods for Treating CD30+ Cancer | |
| CN107735105B (zh) | 抗ntb-a抗体和相关组合物以及方法 | |
| WO2021136483A1 (en) | Anti-trop2 antibodies, antibody-drug conjugates, and application of the same | |
| US11497769B2 (en) | Anti-CD19 antibodies | |
| CN108137706A (zh) | 药物缀合的双特异性抗原结合构建体 | |
| JP2024521667A (ja) | 抗－ｃｄ２０５抗体及び免疫チェックポイント・インヒビターを含む組み合わせ医薬 | |
| AU2024304014A1 (en) | Anti-cd5 antibodies and their uses | |
| WO2026100671A1 (ja) | 抗ｇｐｒｃ５ａ抗体及びその使用 | |
| WO2026060187A1 (en) | Multispecific antibody-drug conjugates (adc) targeting cdh17-expressing tumors and method of making and using thereof |